# **Antifungal Agents**

Lecturer:Prof.Dr.Adnan H.Alhamdani college of Medicine
University of Al-Qadisiyah

#### Introduction

- Since fungi are eukaryotic, antibacterial agents are useless in eradicating mycoses.
- The first antibiotics that could inhibit eukaryotic fungal pathogens with out having a similar effect on the eukaryotic human host cells become available in 1959.
- Before that time, disseminated systemic infections by coccidioides and cryptococcus were usually fatal.
- Antibiotics called *Polyenes* and *azoles* are now used with reasonable success for treating fungal infection, depending on the specific disease.

### 7.1. Polyenes

- The most therapeutically valuable of the polyenes are those that bind with ergosterol, the sterol in fungal membranes, creating membrane pores and causing Leakage of cell metabolites.
- Human cells contain cholesterol instead of ergosterol and are there fore not as susceptible as fungi to these agents.
- The sterols in human cells, however, are some what affected by the pollyenes.

## Polynes cont'd...

- Polyenes are among the few antimicrobials available for the treatment of
  - · cryptococcosis,
  - coccidiodomycosis,
  - · aspergillosis,
  - · mycormycosis,
  - candidiasis
  - other potentially fatal systemic fungal infections
- amphoteriain B, and Nystalin the drug in polyene group

### 7.2. Azoles

- •The azoles are another group of synthetic compounds that interfere with the cell membrane of fungi.
- •Unlike the polyenes, these compounds inhibit the synthesis of ergosterol.
- •One group of azoles, the imidazoles, is effective broad spectrum antifungal drugs with few or no serious side effects.
- •But there are other drugs in this group, such as clotrimazole, miconazole and ketoconazole.

### Azoles cont'd...

- Another group of azoles are the triazole derivatives,
- It includes fluconazole and itraconazole
- These drugs have fewer side effects than the imidazoles for
- Effective against cryptococcus and oral candida infections in AIDS patients e.g. Fluconzole

# Summary of the commonly used Antifungal drugs

### **Amphotericin B**

- Is a polyene anti fungal agent administered intravenously
   (IV)
- Causes nephrotoxicity
- Is the drug of choice in most life threatening fungal infections

# 5-Fluors cytosine (5-Fc, flucytosine)

- Is an antimetabolic that is administered orally
- Is used primarily incombination with amphotericin B in the treatment of cryptococcal meningitis or alone at high strength to irrigate the bladder in the treatment of yeast infections.
- Some fungal infections develop a resistance to the drug.

### Miconazode

- Is an imidazole requiring IV administration and exhibiting greater toxicity than ketoconzole
- Is used topically for mucocutaneous infections
- Ketoconazole
- Is an orally administered imidazole
- Can be used in non life- threatening systemic fungal infections and chronic mucocutaneous candidiasis
- It may be used in many other cutaneous infections

### Ketoconazol cont'd

- It is effective against Aspergillus
- It is used in AIDS patients to reduce recurring fungal infections such as Cryptococcus
- Is administered orally to treat mucoctuaneous infections

| Features of Antifungal Agents |  |  |                   |  |
|-------------------------------|--|--|-------------------|--|
| AGENT                         | MECHANISM OF ACTION                          | MECHANISM OF<br>RESISTANCE   | ROUTE             | CLINICAL USE   |
| POLYENES                      |  |  |                   |  |
| Nystatin                      | Membrane disruption                          | Sterol modification  | Topical           | Most fungi   |
| Amphotericin B                | Membrane disruption                          | Sterol modification  | Intravenous       | Most fungi   |
| Azoles                        |  |  |                   |  |
| Ketoconazole                  | Demethylase block of ergosterol synthesis    | Active efflux,<br>demethylase<br>alteration, or<br>overproduction <sup>a</sup> | Oral              | Candida, Cryptococcus,<br>dimorphic fungi <sup>b</sup>                               |
| Fluconazole                   | Demethylase block of ergosterol synthesis    | Active efflux,<br>demethylase<br>alteration, or<br>overproduction <sup>a</sup> | Oral, intravenous | Candida, Cryptococcus,<br>dimorphic fungi  |
| Itraconazole                  | Demethylase block of ergosterol synthesis    | Active efflux,<br>demethylase<br>alteration, or<br>overproduction <sup>a</sup> | Oral, intravenous | Candida, Cryptococcus,<br>dimorphic fungi,<br>invasive molds<br>(Aspergillus)        |
| Clotrimazole                  | Demethylase block of<br>ergosterol synthesis | Unknown <sup>c</sup>   | Topical           | Candida, some other yeasts   |
| Miconazole                    | Demethylase block of<br>ergosterol synthesis | Unknown <sup>c</sup>   | Topical           | Candida, some other yeasts   |
| Voriconazole                  | Demethylase block of<br>ergosterol synthesis | Unknown <sup>c</sup>   | Oral, intravenous | Candida, some other yeasts and molds   |
| ALLYLAMINES                   |  |  |                   |  |
| Terbinafine                   | Squalene accumulation                        | ?Active efflux   | Oral              | Dermatophytes,<br>combined with<br>azoles for <i>Candida</i> ,<br><i>Aspergillus</i> |
| Naftifine                     | Squalene accumulation                        | Unknown  | Topical           | Dermatophytes  |

Adopted from Sherris Medical Microbiology